|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
CTG007609507 |
| 003 |
DE-627 |
| 005 |
20230425181926.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210512s2021 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)CTG007609507
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)IRCT20200329046892N2
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a Effect of tofacitinib in COVID-19
|b Effectiveness evaluation of Tofacitinib plus Remdesivir in comparison with Remdesivir in the treatment of adult patients with severe COVID-19 A randomized double-blind placebo-included clinical trial
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 2021-03-09, Last updated: 2022-11-24
|
| 650 |
|
4 |
|a Medical Condition: Condition 1: COVID-19. Condition 2: COVID-19. virus identified virus not identified; Clinically-epidemiologically diagnosed COVID-19; Probable COVID-19; Suspected COVID-19;U07.1;U07.2
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 2/Phase 3
|
| 650 |
|
4 |
|a Recruitment Status: Recruiting
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2021) vom: 26. Apr.
|
| 773 |
1 |
8 |
|g year:2021
|g day:26
|g month:04
|
| 856 |
4 |
0 |
|u http://en.irct.ir/trial/54800
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2021
|b 26
|c 04
|
Klinische Studie